Diasorin
Multinational biotech company.
Launch date
Employees
Market cap
€5.4b
Enterprise valuation
€6.3b (Public information from Sep 2024)
Share price
€104.2 DIA.MI
Saluggia Piedmont (HQ & founding location)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 881m | 1.2b | 1.4b | 1.1b | 1.2b | 1.3b | 1.4b |
| % growth | 25 % | 40 % | 10 % | (16 %) | 4 % | 8 % | 8 % |
| EBITDA | 392m | 539m | 534m | 388m | 390m | 430m | 483m |
| % EBITDA margin | 44 % | 44 % | 39 % | 34 % | 33 % | 33 % | 35 % |
| Profit | 248m | 311m | 241m | 165m | 190m | 218m | 251m |
| % profit margin | 28 % | 25 % | 18 % | 14 % | 16 % | 17 % | 18 % |
| EV / revenue | 10.2x | 8.2x | 5.8x | 5.0x | 5.2x | 4.7x | 4.2x |
| EV / EBITDA | 22.9x | 18.8x | 14.7x | 14.8x | 15.9x | 14.1x | 12.2x |
| R&D budget | 50.8m | 70.1m | 96.9m | - | - | - | - |
| R&D % of revenue | 6 % | 6 % | 7 % | - | - | - | - |
Source: Dealroom estimates
